S&P Futures
3,754.00 -35.50 (-0.94%) Dow Futures
30,505.00 -276.00 (-0.90%) Nasdaq Futures
11,410.00 -119.50 (-1.04%) Russell 2000 Futures
1,685.80 -22.20 (-1.30%) Crude Oil
105.14 -0.62 (-0.59%) Gold
1,798.30 -9.00 (-0.50%)
Ionis Pharmaceuticals, Inc. (IONS)
After hours:
Chart Events
Performance Outlook
| Previous Close | 37.56 |
| Open | 37.00 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 1000 |
| Day's Range | 36.68 - 37.76 |
| 52 Week Range | 25.04 - 44.42 |
| Volume | |
| Avg. Volume | 1,107,180 |
| Market Cap | 5.228B |
| Beta (5Y Monthly) | 0.82 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.37 |
| Earnings Date | Feb 22, 2022 - Feb 28, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 47.39 |
- PR Newswire
Ionis announces presentation of positive Phase 2b data for chronic hepatitis B treatment at the EASL International Liver Congress™
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), today announced that GSK presented positive results from an interim analysis of the Phase 2b B-Clear clinical study of bepirovirsen (formerly IONIS-HBVRx), an investigational antisense medicine for the treatment of patients with chronic hepatitis B virus (CHB).
- MarketWatch
AstraZeneca, Ionis plan to seek FDA approval for rare-disease therapy this year
U.S.-listed shares of AstraZeneca were up 2.5% in trading on Tuesday after the company said an experimental therapy for hereditary transthyretin-mediated amyloid polyneuropathy met its primary endpoints in a Phase 3 clinical trial. AstraZeneca is developing eplontersen with Ionis Pharmaceuticals Inc. ; shares in Ionis were up 5.1% on Tuesday. The rare disease can cause nerve damage and motor disability and affects about 40,000 people worldwide, the companies said. They also said they plan to see
- Zacks
Ionis (IONS), AstraZeneca's Amyloidosis Drug Meets Study Goals
Ionis (IONS), along with partner AstraZeneca, reports positive data from a phase III study, which is evaluating eplontersen in hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
